Vanda Pharmaceuticals, Inc. (VNDA) Q4 2024 Earnings Call Transcript
…
3,970€
-4,11%
Echtzeit-Aktienkurs Vanda Pharmaceuticals Inc.
Bid:
Ask:
Nachrichten zur Vanda Pharmaceuticals Inc. Aktie
Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Tops Revenue Estimates
Vanda (VNDA) delivered earnings and revenue surprises of 42.86% and 4.28%, respectively, for the quarter ended December 2024. Do the…
Vanda Pharmaceuticals: Net-Net Status Presents A Trading Opportunity
…
Vanda Pharmaceuticals Inc. (VNDA) Q3 2024 Earnings Call Transcript
…
Vanda Pharmaceuticals rejects Cycle Pharmas second takeover offer By Reuters
Vanda Pharmaceuticals rejects Cycle Pharmas second takeover offer…
Cycle Pharmaceuticals Stands By $488 Million Offer for Vanda
Cycle Pharmaceuticals Ltd. is still interested in acquiring Vanda Pharmaceuticals Inc. after one of Vanda’s drugs failed to receive regulatory…
Vanda Pharmaceuticals: I Believe That The Bidding War Is Not Over
…
Court advances Vanda Pharmaceuticals patent case By Investing.com
Court advances Vanda Pharmaceuticals patent case…
Vanda Pharmaceuticals drops after Future Pak walks away
…
Vanda Pharmaceuticals: Undervalued With Promising Pipeline And Acquisition Interest
…
Global Bipolar Disorder Market Size To Exceed USD 6.47 Billion By 2033 | CAGR Of 1.98%
The Global Bipolar Disorder Market Size was Valued at USD 5.32 Billion in 2023, the Worldwide Bipolar Disorder Market Size…
Vanda Pharmaceuticals rejects sweetened bid from Future Pak
…
Vanda Pharmaceuticals, Inc. (VNDA) Q1 2024 Earnings Call Transcript
…
U.S. Supreme Court rejects Vanda Pharmaceuticals case over sleep-drug patents By Reuters
U.S. Supreme Court rejects Vanda Pharmaceuticals case over sleep-drug patents…
Vanda Pharmaceuticals: Fanapt Bipolar Win Doesnt Change Much
…
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceutical Inc. - VNDA
NEW YORK, March 31, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceutical Inc. - VNDA
NEW YORK, March 23, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…
Dyspepsia Drug Pipeline Insight Report 2024 Featuring Vanda Pharmaceuticals, Dong-A ST, and Dexa Medica Group
Dublin, March 04, 2024 (GLOBE NEWSWIRE) -- The "Dyspepsia - Pipeline Insight, 2024" report has been added to…